<DOC>
	<DOCNO>NCT01968213</DOCNO>
	<brief_summary>Patients enrol study stratify 3 group base gene mutation identify tumor tissue . The purpose study evaluate patient response maintenance treatment rucaparib versus placebo . Response treatment analyze base homologous recombination ( HR ) status tumor sample .</brief_summary>
	<brief_title>A Study Rucaparib Switch Maintenance Following Platinum-Based Chemotherapy Patients With Platinum-Sensitive , High-Grade Serous Endometrioid Epithelial Ovarian , Primary Peritoneal Fallopian Tube Cancer</brief_title>
	<detailed_description>Rucaparib orally available , small molecule inhibitor poly-adenosine diphosphate [ ADP ] ribose polymerase ( PARP ) develop treatment ovarian cancer associate homologous recombination ( HR ) DNA repair deficiency ( HRD ) . Clinical data show ovarian cancer patient without evidence gBRCA mutation benefit treatment PARP maintenance treatment PARP inhibitor follow response platinum-based treatment increase PFS patient ovarian cancer . While patient BRCA mutation derive benefit , patient without evidence BRCA mutation also derive significant benefit . Patients enrol study stratify 3 group base tumor HRD status . The purpose study identify group patient likely benefit treatment rucaparib . It anticipate rucaparib provide therapeutic benefit increase PFS patient HRD associate BRCA gene mutation HR gene alteration .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Rucaparib</mesh_term>
	<criteria>Confirmed diagnosis highgrade serous endometrioid epithelial ovarian , primary peritoneal , fallopian tube cancer . Received â‰¥2 prior platinumbased treatment regimens include platinum base regimen must administer immediately prior maintenance therapy trial . Received 1 nonplatinum chemotherapy regimen . Prior hormonal therapy count nonplatinum regimen . Must least 6month diseasefree period follow prior treatment penultimate platinumbased chemotherapy achieve response . For last chemotherapy course prior study entry , patient must receive platinumbased doublet chemotherapy regimen achieve CR PR ( define RECIST ) and/or GCIG CA125 response . Have sufficient archival tumor tissue analysis . History prior cancer except nonmelanoma skin cancer , breast cancer curatively &gt; 3 year ago , curatively treat solid tumor ( &gt; 5 year ago without evidence recurrence ) , synchronous endometrial cancer ( Stage 1A ) ovarian cancer . Prior treatment PARP inhibitor , include rucaparib . Patients receive prior iniparib eligible . Untreated symptomatic central nervous system metastasis . Preexisting duodental stent and/or gastrointestinal disorder defect would , opinion Investigator , interfere absorption study drug . Required drainage ascites final 2 cycle last platinumbased regimen and/or period last dose chemotherapy regimen randomization maintenance treatment study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ARIEL3</keyword>
	<keyword>ARIEL 3</keyword>
	<keyword>platinum sensitive</keyword>
	<keyword>PARP Inhibitor</keyword>
	<keyword>rucaparib</keyword>
	<keyword>homologous recombination</keyword>
	<keyword>homologous recombination deficiency</keyword>
	<keyword>CO-338</keyword>
	<keyword>PF 01367338</keyword>
	<keyword>AG 14699</keyword>
	<keyword>platinum sensitive ovarian cancer</keyword>
	<keyword>platinum sensitive fallopian tube cancer</keyword>
	<keyword>platinum sensitive primary peritoneal cancer</keyword>
	<keyword>platinum sensitive peritoneal cancer</keyword>
	<keyword>gynecological cancer</keyword>
	<keyword>Clovis</keyword>
	<keyword>Clovis Oncology</keyword>
</DOC>